Common atrial flutter catheter ablation without discontinuing oral anticoagulation
| Autor: | Rosa Montes de Oca, Jose Lopez-Sendon, Sergio Castrejón, Carlos Escobar, Marta Ortega, José L. Merino |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Rivaroxaban Acenocoumarol business.industry medicine.medical_treatment Catheter ablation 030204 cardiovascular system & hematology Ablation medicine.disease Pericardial effusion Dabigatran Surgery 03 medical and health sciences 0302 clinical medicine Anesthesia medicine Molecular Medicine Apixaban cardiovascular diseases 030212 general & internal medicine Cardiology and Cardiovascular Medicine business Atrial flutter medicine.drug |
| Zdroj: | Future cardiology. 13(5) |
| ISSN: | 1744-8298 |
| Popis: | Aim: To determine if performing catheter ablation under oral anticoagulation is associated with a higher risk of thromboembolic or bleeding complications. Methods: Patients with common atrial flutter that underwent catheter ablation of the cavo-tricuspid isthmus were consecutively included in the study. All patients were taking oral anticoagulants at least 3 weeks before the ablation. Results: A total of 102 patients (mean age 67.9 ± 10.3 years; 83.3% male) were included. Among them 80.6% patients were taking acenocoumarol, 10.7% dabigatran, 7.8% rivaroxaban and 0.9% apixaban. After the procedure, no new pericardial effusion or major complications were detected. In the study 7.8% of patients had mild hematoma in the puncture site. Conclusion: Performing common atrial flutter catheter ablation under oral anticoagulation is associated with low risk of complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|